{"nctId":"NCT01565694","briefTitle":"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity","startDateStruct":{"date":"2012-08-14","type":"ACTUAL"},"conditions":["Neurogenic Detrusor Overactivity"],"count":76,"armGroups":[{"label":"Solifenacin succinate","type":"EXPERIMENTAL","interventionNames":["Drug: Solifenacin succinate"]}],"interventions":[{"name":"Solifenacin succinate","otherNames":["YM905"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of NDO, confirmed by urodynamics\n* Practicing clean intermittent catheterization (CIC)\n* Currently on treatment with an antimuscarinic drug\n\nExclusion Criteria:\n\n* Known genitourinary condition (other than NDO) that may cause incontinence\n* Bladder augmentation surgery\n* Current Faecal impaction\n* Electro-stimulation therapy within 2 weeks prior to screening and at any time during the study\n* Subjects with the following gastro-intestinal problems: partial or complete obstruction, decreased motility like paralytic ileus, subjects at risk of gastric retention\n* Reflux grade 3 or 4\n* Current urinary tract infection (UTI)\n* Subject has severe renal impairment (glomerular filtration rate \\< 30 ml/min)\n* Subject has severe hepatic impairment (Child-Pugh score \\> 9).\n* Subject has received intra-vesical botulinum toxin within 9 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)","description":"During urodynamic assessments, the bladder was filled until voiding/leakage begins, or until it was stopped because either the participant experiences pain or discomfort or 135% of expected bladder capacity for age has been reached. MCC is the maximum bladder capacity reached during filling cystometry before either leakage or pain/discomfort was observed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":"107.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":"107.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Last Possible Titration Step in Maximum Cystometric Capacity","description":"During urodynamic assessments, the bladder was filled until voiding/leakage begins, or until it was stopped because either the participant experiences pain or discomfort or 135% of expected bladder capacity for age has been reached. MCC is the maximum bladder capacity reached during filling cystometry before either leakage or pain/discomfort was observed. Based on study requirements, the last possible titration step was Week 9 for participants enrolled under versions 1.0 and 1.1 and Week 12 under later versions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":"105.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bladder Compliance","description":"Bladder compliance gives an indication of the elasticity of the bladder wall and was calculated by dividing the change in volume by the change in detrusor pressure during the filling of the bladder.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"28.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"27.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bladder Volume (mL) Until First Detrusor Contraction > 15 cmH2O as a Percentage of Expected Bladder Capacity (EBC)","description":"Change from baseline in the bladder volume was calculated using urodyanamic assessments. During urodynamic assessments, the bladder is filled until voiding/leakage begins, or until it is stopped because either the subject experiences pain or discomfort or 135% of expected bladder capacity for age has been reached. If no detrusor contraction of at least 15 cmH2O occurs, the bladder volume was imputed with MCC.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bladder Volume at 30 cmH2O Detrusor Pressure","description":"Bladder volumes at 30 cm H2O detrusor pressure was calculated using the urodynamic assessments. During urodynamic assessments, the bladder is filled until voiding/leakage begins, or until it is stopped because either the participants experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":"80.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":"88.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bladder Volume at 40 cmH2O Detrusor Pressure","description":"Bladder volumes at 40 cm H2O detrusor pressure were calculated using urodynamic assessments. During urodynamic assessments, the bladder is filled until voiding/leakage begins, or until it is stopped because either the subject experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":"44.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":"52.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until End of Bladder Filling","description":"Change from baseline in number of overactive detrusor contractions until end of bladder filling was measured by urodynamic testing. If leakage occurred, the \"Detrusor pressure at leakage\" was recorded otherwise the volume of fluid instilled into the bladder was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"6.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Detrusor Pressure at the End of Bladder Filling","description":"The bladder was filled until voiding/leakage began or until it was stopped because either the participant experiences pain or discomfort or 135% of expected bladder capacity for age has been reached. Pressure was recorded for an extra 5 minutes after leakage began or the end of bladder-filling, whichever is sooner.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"33.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"32.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average Catheterized Volume Per Catheterization","description":"The average catheterized volume per catheterization was calculated using all available (non-zero) catheterized volumes recorded over both of the 2 measuring days in the diary, whether or not these 2 days are concurrent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.23","spread":"48.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.86","spread":"50.98"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Maximum Catheterized Volume","description":"The maximum catheterized volume per day was calculated using all available (non-zero) catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days were concurrent. The maximum value was calculated separately for each measuring day and the mean of these two values was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.45","spread":"88.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.63","spread":"88.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average First Morning Catheterized Volume","description":"The average first morning catheterized volume was calculated as the average of the available first morning catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days are concurrent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.24","spread":"72.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.21","spread":"73.40"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours","description":"The mean of the number of incontinence episodes per 24h was calculated as the mean over the valid diary days in the 7-day diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"2.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.62","spread":"2.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Dry (Incontinence-Free) Days Per 7 Days","description":"The number of incontinence-free days was calculated from the 7-day micturition diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"2.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"2.86"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Dry (Incontinence-Free) Nights Per 7 Days","description":"The number of incontinence-free nights was calculated from the 7-day micturition diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"3.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"3.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life [QoL] (PinQ Questionnaire Score)","description":"Pediatric Incontinence Questionnaire (PinQ) is a 20-item questionnaire addressing quality of life for participants with bladder disorders. Each question was answered on a scale from 0 (no, never) to 4 (all the time). The total score ranged from 0 to 80, with higher scores indicated more impact on the quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"A treatment-emergent adverse event (TEAE) was defined as an adverse event observed after starting administration of the first dose of study medication on Day 1. All adverse events collected within 7 days after taking the last dose of study drug were counted as a TEAE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":76},"commonTop":["Urinary tract infection bacterial","Urinary tract infection","Constipation","Escherichia urinary tract infection","Nasopharyngitis"]}}}